A new study conducted by a research team from Texas A&M University and the University of Texas Medical Branch (UTMB) shows that federally approved cardiac drugs have shown significant effectiveness in interfering with SARS-CoV-2̵
The Bepril drug called “Vascor” is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of angina (a type of heart disease).
The team leader is a professor of the Department of Chemistry at Texas A&M University, the holder of Professor Gladcon, Wenshe Ray Liu, a professor in the Faculty of Science, and Zeng Jiande, a professor and director of the SARS / MERS / COVID-19 laboratory at UTMB. Liu also holds joint faculty positions at Texas A&M’s School of Medicine, College of Agriculture and Life Sciences.
Liu said: “Currently, there is only one drug, remdesivir, which does not provide limited benefits for COVID-19 patients, and this virus is easy to evade.” “It is imperative to find alternative drugs. Our team screened 30 A variety of FDA/European Medicines Agency approved drugs, these drugs have the ability to inhibit SARS-COV-2 from entering human cells. The study found that bepredil has the greatest potential for the treatment of COVID-19. Therefore, we advocate the cooperation with SARS -Bepril is seriously considered in clinical trials related to CoV-2.”
The Texas A&M-UTMB study is now published on the peer-reviewed website Proceedings of the National Academy of Sciences (PNAS), and is scheduled to be published in print on March 9.
The team includes six other researchers from Texas A&M and four researchers from UTMB, and now plans to extend their work to animal models with clinical trial potential.
Track the latest news about the coronavirus (COVID-19) outbreak
Erol C. Vatansever et al. Bepredil has the ability to resist SARS-CoV-2 in vitro, Proceedings of the National Academy of Sciences (2021). DOI: 10.1073 / pnas.2012201118
Courtesy of Texas A&M University
Citation: The research team has identified a potential drug for the treatment of SARS-CoV-2 (February 22, 2021), which will be available from https://medicalxpress.com/news/2021-02-team-potential on February 23, 2021 -drug-sars-cov-.html search
This document is protected by copyright. Except for any fair transactions for private learning or research purposes, no content may be copied without written permission. The content is for reference only.